satralizumab   Click here for help

GtoPdb Ligand ID: 9093

Synonyms: Enspryng® | RG-6168 | RG6168 | SA-237 | SA237 | sapelizumab (deprecated INN) | satralizumab-mwge
Approved drug Immunopharmacology Ligand
satralizumab is an approved drug (Canada, Japan and FDA (2020), EMA (2021))
Compound class: Antibody
Comment: Satralizumab (previously referred to using the replaced INN sapelizumab) is an investigational humanized monoclonal antibody targeting the IL-6 receptor, with immunomodulatory potential. This antibody is an improved version of tocilizumab, with enhanced antigen-neutralizing ability and pharmacokinetics suitable for less frequent administration [2].
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record. Peptide BLAST searches reveal identical matches between the heavy and light chain sequences as annotated in IMGT and SEQ IDs 26 and 29 respectively claimed in patent US8562991 [2]. This matches satralizumab to the Fv4-M73 construct in the patent.
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
No information available.
Summary of Clinical Use Click here for help
Satralizumab was granted EMA orphan drug designation for neuromyelitis optica (NMO) in June 2016. It received its first national approval from Canada in June 2020 [1], and from Japan slightly later that year, for the treatment of neuromyelitis optica spectrum disorder (NMOSD), FDA approval followed in August 2020 with the indication specified as anti-aquaporin-4 (AQP4) antibody positive NMOSD.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT02073279 Efficacy and Safety Study of Satralizumab (SA237) as Monotherapy to Treat Participants With Neuromyelitis Optica (NMO) and Neuromyelitis Optica Spectrum Disorder (NMOSD) Phase 3 Interventional Hoffmann-La Roche 3